Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Cagrilintide B vs D in Overweight and Obesity
NCT07605052Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- May 2026
- Primary completion
- Aug 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of cagrilintide in obesity (2 arms), sponsored by Novo Nordisk. Primary endpoints: Area under the total cagrilintide concentration-time curve at steady state and Maximum observed concentration of total cagrilintide at steady state. Started May 2026; status: completed.
02
Drugs
cagrilintide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07605052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07605052.